Latest News
CelLBxHealth study highlights Parsortix potential in ADC biomarker monitoring
3 August 2026 - CTC intelligence company CelLBxHealth plc (AIM: CLBX) on Monday announced a peer-reviewed study demonstrating the use of its Parsortix platform to detect antibody-drug conjugate (ADC)-relevant targets on circulating tumour cells (CTCs...
Qatar approves Zepzelca combination as first-line maintenance therapy for extensive-stage small cell lung cancer
3 August 2026 - Swedish pharmaceutical company Immedica, backed by investment firms KKR & Co Inc (NYSE:KKR) and Impilo, announced on Monday that Qatar's Ministry of Public Health has approved Zepzelca (lurbinectedin) in combination with atez...
Coiled Therapeutics doses first patient with optimised AO-252 formulation
3 August 2026 - Coiled Therapeutics plc (AIM: COIL) (OTCQB: COTXF), a clinical-stage precision oncology company, announced on Monday that it has dosed the first patient in the US with an optimised lipid-based oral formulation of its Phase I cancer th...
Ridgetech reports financial results for fiscal year to March 2026
3 August 2026 - Ridgetech Inc (Nasdaq:RDGT), a wholesale distributor of pharmaceutical and other healthcare products in China, on Friday reported its financial results for the fiscal year ended 31 March 2026.Full-year revenue was USD132.16m, up 10.2%...
CREATE Medicines agrees strategic research collaboration with Australia's Monash University
3 August 2026 - CREATE Medicines Inc, a clinical-stage biotechnology company, announced on Friday that it has entered into a strategic research collaboration with Australia's Monash University and its Monash Institute of Pharmaceutical Sciences ...